Kikutarou Endou
Chiba University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kikutarou Endou.
Microbiology and Immunology | 1990
Mayumi Matsuoka; Kikutarou Endou; Yoshinori Nakajima
Four out of more than 8,200 Staphylococcus aureus strains isolated in Japan between 1961 and 1980 were constitutively resistant to a variety of macrolide antibiotics except tylosin and rokitamycin, but susceptible to lincosamide and streptogramin type B antibiotics (PM). The data obtained by agarose gel electrophoresis, CsCl‐ethidium bromide density gradient analysis, diagnosis with ATP‐dependent deoxyribonuclease, and a test transducing into a rec− mutant with phage 80L2 propagated on PM‐resistant S. aureus all suggested that the determinant for the PM‐resistance is located in chromosome.
Yakugaku Zasshi-journal of The Pharmaceutical Society of Japan | 1994
Hiroyuki Kobayashi; Kikutarou Endou; Yoshinori Nakajima
Using Staphylococcus aureus ISP447 strain, which shows inducible resistance to macrolide-lincosamide-streptogramin B (MLS) antibiotics, the extent of MLS-resistance induced by several macrolide antibiotics [erythromycin (EM), oleandomycin (OL), or roxithromycin (RXM)] was determined in terms of a relative ratio of a growth rate of the induced cells in the presence of a challenging drug, rokitamycin (RKM), to that of uninduced cells in the absence of RKM. The ratio was referred to as a relative inducibility (%). The inducibility was obtained at an optimum-induced condition by considering the following factors: (1) exponentially growing cells, (2) the optimum concentration of an inducer drug, i.e., 50, 150, and 150 ng/ml for EM, OL, and RXM, respectively, (3) a 3-h previous incubation at 37 degrees C in the presence of the inducer, and (4) 300 ng of RKM/ml, which is found to be optimum for induced cells to challenge, because of having no inducer activity. Using these qualification methods, inducibilities of EM, OL, and RXM as an inducer were 100.4, 27.9 and 81.1%, respectively. This method is allowed to be useful for the analysis of a structure-inducibility relationship.
Biological & Pharmaceutical Bulletin | 1995
Mayumi Matsuoka; Kikutarou Endou; Shiori Saitoh; Mika Katoh; Yoshinori Nakajima
The Journal of Antibiotics | 1993
Kikutarou Endou; Mayumi Matsuoka; Hirofumi Taniguchi; Yoshinori Nakajima
Journal of pharmacobio-dynamics | 1992
Yoshinori Nakajima; László Jánosi; Kikutarou Endou; Mayumi Matsuoka; Hajime Hashimoto
Biological & Pharmaceutical Bulletin | 1993
Mayumi Matsuoka; László Jánosi; Kikutarou Endou; Shiori Saitoh; Hajime Hashimoto; Yoshinori Nakajima
Chemical & Pharmaceutical Bulletin | 1985
Setsuko Oikawa; Minoru Tsuda; Kikutarou Endou; Hideko Abe; Mayumi Matsuoka; Yoshinori Nakajima
Journal of pharmacobio-dynamics | 1990
Yoshinori Nakajima; Reiko Takeda; Kato Tani; Kikutarou Endou; Mayumi Matsuoka; Saburo Yamagishi
Journal of pharmacobio-dynamics | 1987
Kikutarou Endou; Mayumi Matsuoka; Yoshinori Nakajima
Journal of pharmacobio-dynamics | 1985
Kikutarou Endou; Mayumi Matsuoka; Hideko Abe; Yoshinori Nakajima